GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis
Status:
Completed
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled,
parallel-group study to evaluate GLPG2737 administered orally b.i.d. for 28 days to adult
male and female subjects with a confirmed diagnosis of cystic fibrosis homozygous for the
F508del CFTR mutation and on stable treatment with Orkambi.